Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says

Dr. Philip Adamson is chief medical officer of Abbott’s heart failure business [Photo courtesy of Abbott]Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body.

What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection, even in mild cases. This once-in-a-century pandemic that has already killed millions across the globe could leave hundreds of millions more with chronic conditions varying in acuity.

“Not only is the viral infection bad for some people, but the subsequent body’s reaction to the viral illness in many people is remarkable. I personally have never seen anything like it,” said Dr. Philip Adamson, chief medical officer of Abbott’s heart failure business. “I’ve lived through and trained through the AIDS epidemic and learned a lot abo…

Read more
  • 0

Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says

Dr. Philip Adamson is chief medical officer of Abbott’s heart failure business [Photo courtesy of Abbott]

Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body.

What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection, even in mild cases. This once-in-a-century pandemic that has already killed millions across the globe could leave hundreds of millions more with chronic conditions varying in acuity.

“Not only is the viral infection bad for some people, but the subsequent body’s reaction to the viral illness in many people is remarkable. I personally have never seen anything like it,” said Dr. Philip Adamson, chief medical officer of Abbott’s heart failure business. “I’ve lived throu…

Read more
  • 0

Recurrent clinical trial events: Analyzing methodologies with cardiology examples 

Photo by Andrea Piacquadio from Pexels

Cardiology trials often adopt composite endpoints that combine several events of clinical interest as the primary efficacy outcome.

Time-to-first-event approaches follow the recommendations of regulatory agencies. But composite outcomes that only consider the first event are suboptimal for a chronic disease such as heart failure (HF), which is characterized by recurrent HF hospitalizations since repeat events within individuals are ignored in analyses.

Recurrent HF hospitalizations indicate a worsening condition and disease progression, so considering all HF hospitalizations in analysis more accurately assesses the effect of treatment on the true disease burden. Currently, there is no recommendation as to the preferred approach. The CHARM-Preserved trial shows the impact of analyzing only the time-to-first event and ignoring repeat hospitalizations.1

Of th…

Read more
  • 0